OPKO Health, Inc.

NASDAQ:OPK

Biotechnology

Healthcare
$1.69 +0.52%

+$0.01 today

Market cap
$1.25B
Beta
1.49
P/E (TTM)
-5.1
EPS (TTM)
-$0.28
52W Low $0.98High $1.60

Volume 3.06M

Average 2.59M

OPK Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

OPKO Health, Inc.NASDAQ: OPK

Accounts Payables · Q1 FY2026 · quarter ended Mar 2026

Accounts payables dips below year-ago levels

Q1 FY2026 accounts payables of $3.5M fell 69.5% year over year, behind the +85.3% change in trailing-twelve-month accounts payables. Over 3 fiscal years it compounded at +14.8% a year.

Context

  • Accounts payables amounted to 2.3% of revenue in FY2025, down 0.6 pp from a year earlier.
  • Accounts payables increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -69.5% toward the trailing-twelve-month pace of +85.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.5M+120.5% QoQ
Last fiscal yearDec 2025
-$14.22M-31.2% YoY
LTMMar 2026
-$22.2M+85.3% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-69.5%——
1 year-31.2%——
3-year CAGR+14.8%——
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
(14.22M) USD
Year-over-year change
+31.2%

Accounts Payables vs competitors

How OPK compares with its peers on the latest reported figures

  • OPK's LTM Mar 2026 accounts payables of $22.2M is the 3rd largest of the 11 companies compared; the peer median is $2.53M.
  • Its year-over-year change of +85.3% is the 5th highest of 8, against a peer median of +235.6%.
  • Accounts payables amounts to 3.8% of revenue for OPK, versus a peer median of 1.0%.
OPK Competitors Peer median
Accounts Payables for OPK and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GHGuardant Health, Inc.LTM Sep 2026$41.71M ——3.3%
NTRANatera, Inc.LTM Jun 2026$29.39M +734.8%-48.3%1.1%
OPKOPKO Health, Inc.LTM Mar 2026$22.2M +85.3%+14.8%3.8%
NEONeoGenomics, Inc.LTM Jun 2026$16.49M -289.5%—2.2%
CSTLCastle Biosciences, Inc.LTM Mar 2026$5.66M +269.6%+74.2%1.7%
MYGNMyriad Genetics, Inc.LTM Mar 2026$4M +385.7%-26.3%0.5%
BLLNBillionToOne, Inc.LTM Jun 2026$3.33M ——0.8%
PSNLPersonalis, Inc.LTM Mar 2026$1.73M +235.6%+13.8%2.7%
FLGTFulgent Genetics, Inc.LTM Mar 2026$800K -69.8%—0.2%
MDXHMDxHealth S.A.FY2025$550K ——0.5%
XGNExagen Inc.LTM Mar 2026$230K -110.5%-64.0%0.3%
Peer median (excluding OPK) $2.53M+235.6%-26.3%1.0%

Competitors are the stored peer set for OPK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(30.14M)(328.41M)(188.86M)(53.22M)(225.68M)
Depreciation & Amortization78.72M108.66M105.3M98.18M91.63M
Deferred Income Tax10.16M(74.41M)146K14.74M(15M)
Stock-Based Compensation13.63M18.51M11.41M11.05M10.71M
Change in Working Capital(20.48M)42.65M21.8M32.18M(41.18M)
Accounts Receivables5.23M128.6M3.41M(220K)30.21M
Inventory30.68M13.66M15.2M4.22M(4.12M)
Accounts Payables(10.85M)(9.39M)2.83M(20.66M)(14.22M)
Other Working Capital(45.55M)(90.22M)363K48.84M(53.06M)
Other Non-Cash Items(13.55M)137.8M22.01M(286.41M)976K
Operating Cash Flow38.34M(95.19M)(28.2M)(183.49M)(178.54M)
Capital Expenditures(32.16M)(24.58M)(16.28M)(25.01M)(12.28M)
Acquisitions (Net)(6M)(1.76M)(5M)00
Purchases of Investments00000
Sales of Investments8.08M115.42M364K166.6M52.18M
Other Investing Activities66.03M1.95M2.71M210.62M190.39M
Investing Cash Flow35.95M91.04M(18.2M)352.21M230.3M
Debt Repayment(11.24M)23.75M(11.03M)287.98M(70.76M)
Common Stock Issued0000(256K)
Common Stock Repurchased000(90.22M)(47.04M)
Dividends Paid00000
Other Financing Activities893K(774K)(272K)(13.59M)0
Financing Cash Flow(10.35M)22.97M(11.3M)184.17M(118.06M)
Effect of Forex Changes(1.44M)(339K)388K(3.16M)3.43M
Net Change in Cash62.5M18.48M(57.31M)349.73M(62.87M)
Free Cash Flow6.18M(119.77M)(44.47M)(208.5M)(190.82M)

OPKO Health, Inc.

NASDAQ:OPK

Intrinsic Alpha fair value

Locked

Current Price

$1.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.